51. 全身性強皮症 Scleroderma Clinical trials / Disease details


臨床試験数 : 525 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02356809
(ClinicalTrials.gov)
March 201526/1/2015Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's PhenomenonSafety and Efficacy Study of Pl-vegf165 to Treat Secondary Raynaud's Phenomenon Caused by Systemic SclerodermaSecondary Raynaud's PhenomenonDrug: NeovasculgenHuman Stem Cell Institute, RussiaInstitute of Rheumatology-Russian Academy of Medical SciencesNot yet recruiting18 Years65 YearsBoth30Phase 1/Phase 2Russian Federation